A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma. - Hamilton AK; Radaoui AB; Tsang M; Martinez D; Conkrite KL; Patel K; Sidoli S; Delaidelli A; Modi A; Rokita JL; Lane MV; Hartnett N; et al. (Cancer cell, 2024)